Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
It is estimated that epistaxis results in 4.5 million emergency department visits per year
throughout the United States. Due to the adverse effects of standard treatment options for
epistaxis, tranexamic acid (TXA) may be considered an attractive option. In previous studies,
when used with nasal packing, TXA showed faster time to control of bleeding. The goal of this
study is to determine the efficacy and safety of topical intranasal TXA applied via atomizer
for patients with epistaxis who present to the emergency department.